完全血管外生物可吸收封堵器减少外周介入入路并发症
该单中心回顾性研究分析了2015至2020年507例外周动脉介入手术,比较完全血管外生物可吸收封堵(TEBC)与手动压迫(MC)的入路并发症。TEBC组无急性动脉缺血发生,轻微并发症显著减少(OR=0.39 [0.19-0.75];P<0.01),主要并发症两组无差异(OR=1.45 [0.27-7.79];P=0.66)。
要点
- TEBC组急性动脉缺血发生率为0%,MC组为1.3%。
- TEBC显著减少轻微入路并发症(OR=0.39 [0.19-0.75];P<0.01)。
- 主要入路并发症两组无显著差异(OR=1.45 [0.27-7.79];P=0.66)。
核心结论
- TEBC用于外周动脉疾病介入术后是安全有效的。
- 本系列中TEBC后无急性动脉缺血发生,且与MC相比TEBC显著降低了轻微入路并发症发生率。
- 鉴于装置的可吸收设计且无任何腔内组件,TEBC可能是外周动脉疾病患者行血管内介入的理想封堵装置。
研究设计与样本
- 单中心回顾性临床研究,纳入2015年至2020年间连续进行的外周介入手术。
- 共507例外周介入手术,涉及345例患者,平均年龄74岁。
- 合并症包括糖尿病(57%)、肥胖(28%)和需要透析的终末期肾衰竭(10%)。
- 介入指征为慢性肢体威胁性缺血(CLTI)(68%)或跛行(32%)。
- 所有手术均采用股动脉入路,逆行为93%、顺行为7%,鞘管尺寸≤5 Fr(21%)、6 Fr(18%)或≥7 Fr(61%)。
主要发现
- 急性动脉缺血在MC组罕见(1.3%),在TEBC组未观察到。
- 需要再次手术的出血和/或假性动脉瘤也罕见(MC组0.3% vs TEBC组1.6%;P=0.64)。
- 多因素分析显示,MC与TEBC的主要入路并发症无差异(OR=1.45 [0.27-7.79];P=0.66)。
- TEBC显著减少了轻微入路并发症(OR=0.39 [0.19-0.75];P<0.01)。
关键数值与推荐
- 主要并发症定义为急性动脉缺血、大出血和/或需要手术的假性动脉瘤的复合终点。
- 轻微并发症定义为短暂性低血压、腹股沟血肿和/或动静脉瘘的集合。
临床怎么用
- 作者认为TEBC在外周动脉疾病介入术后安全有效,且可能为理想封堵装置。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous closure of the access artery has become commonplace after endovascular intervention. In patients with peripheral vascular occlusive disease, however, control of the puncture site is more problematic as the access artery is frequently plaque-laden and stenotic. Ischemic complications in the access extremity are more common in these cases, particularly when using devices that depend on the deployment of prosthetic material within the compromised arterial lumen. The purpose of this retrospective clinical study was to assess the efficacy of totally extravascular bioresorbable closure (TEBC) of the femoral artery puncture sites after percutaneous peripheral intervention (PPI). METHODS: Consecutive PPIs performed at single institution between 2015 and 2020 were studied. Demographic characteristics and the incidence of access complications were recorded. The complication rate of TEBC and manual compression (MC) were analyzed with multivariate regression analysis. Major complications were defined as the composite of acute arterial ischemia, major bleeding, and/or pseudoaneurysm requiring operation. Minor complications were defined as the aggregate of transient hypotension, groin hematoma, and/or arteriovenous fistula. RESULTS: A total of 507 PPIs were performed in 345 patients during the study period. The mean age was 74 years; comorbidities were prevalent, including diabetes (57%), obesity (28%), and end-stage renal failure requiring dialysis (10%). Indications for PPI were either chronic limb-threatening ischemia (CLTI) (68%) or claudication (32%). All procedures were performed using femoral artery access in a retrograde (93%) or antegrade (7%) fashion with ≤5 Fr (21%), 6 Fr (18%), or ≥7 Fr (61%) sheaths. Control of the femoral artery puncture site was achieved by either MC (75%), or TEBC (25%). TEBC became the exclusive closure method in 2019. Acute arterial ischemia rarely complicated MC (1.3%) but was not observed in any patient undergoing TEBC. Bleeding and/or pseudoaneurysms requiring reoperation were also rare (MC 0.3% vs. TEBC 1.6%; P = 0.64). On multivariate analysis, there was no difference in major access complications between MC and TEBC (odds ratio [OR] = 1.45 [0.27-7.79]; P = 0.66), while minor access complications were significantly reduced with the use of TEBC (OR = 0.39 [0.19-0.75]; P < 0.01). CONCLUSION: TEBC after PPI for peripheral arterial disease is safe and effective. There were no instances of acute arterial ischemia following TEBC in this series, and TEBC significantly reduced the incidence of minor access complications compared to MC. Given the bioresorbable design of the device and the lack of an intraluminal component of any kind, TEBC may be the ideal closure device for patients with peripheral arterial disease undergoing endovascular intervention.
引用
- Bystrom PV, Kulangara R, El Khoury R, et al. Totally Extravascular Bioresorbable Closure Reduces Access Complications after Endovascular Peripheral Intervention. Ann Vasc Surg. 2025. PMID: 40316207. doi:10.1016/j.avsg.2025.04.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。